Cargando…

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa

BACKGROUND: Rilpivirine (TMC278LA) is a promising drug for pre-exposure prophylaxis of HIV-1 because of its sub-nanomolar potency and long-acting formulation; however, increasing transmission of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 with potential cross-resistance to rilpivi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Penrose, Kerri J, Brumme, Chanson J, Scoulos-Hanson, Maritsa, Hamanishi, Kristen, Gordon, Kelley, Viana, Raquel V, Wallis, Carole L, Harrigan, P Richard, Mellors, John W, Parikh, Urvi M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890541/ https://www.ncbi.nlm.nih.gov/pubmed/29566538 http://dx.doi.org/10.1177/2040206618762985

Ejemplares similares

Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology
por: Pereira, Mariana, et al.
Publicado: (2023)

Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention
por: Glaubius, Robert L., et al.
Publicado: (2016)

Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost‐effectiveness
por: Glaubius, Robert, et al.
Publicado: (2019)

Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa
por: Wallis, Carole L., et al.
Publicado: (2011)

Alternative Splicing of a Novel Inducible Exon Diversifies the CASK Guanylate Kinase Domain
por: Dembowski, Jill A., et al.
Publicado: (2012)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use
por: Maruapula, Dorcas, et al.
Publicado: (2023)

Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland
por: Parczewski, Miłosz, et al.
Publicado: (2014)

The role of rilpivirine in Southern Africa
por: Moorhouse, Michelle A., et al.
Publicado: (2019)

Estimating the Respective Contributions of Human and Viral Genetic Variation to HIV Control
por: Bartha, István, et al.
Publicado: (2017)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
por: Parikh, Urvi M., et al.
Publicado: (2022)

Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada
por: Rocheleau, Genevieve, et al.
Publicado: (2017)

HIV‐1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial
por: Parikh, Urvi M., et al.
Publicado: (2021)

Direct non-productive HIV-1 infection in a T-cell line is driven by cellular activation state and NFκB
por: Dahabieh, Matthew S, et al.
Publicado: (2014)

Estimation of measurement error in plasma HIV-1 RNA assays near their limit of quantification
por: Lima, Viviane D., et al.
Publicado: (2017)

Biochemical mechanism of clinical resistance to rilpivirine
por: Singh, Kamalendra, et al.
Publicado: (2012)

The development of an effective synthetic route of rilpivirine
por: Zhang, Tao, et al.
Publicado: (2021)

HIV proviral genetic diversity, compartmentalization and inferred dynamics in lung and blood during long-term suppressive antiretroviral therapy
por: Shahid, Aniqa, et al.
Publicado: (2022)

Rates and Correlates of Short Term Virologic Response among Treatment-Naïve HIV-Infected Children Initiating Antiretroviral Therapy in Ethiopia: A Multi-Center Prospective Cohort Study
por: Tadesse, Birkneh Tilahun, et al.
Publicado: (2019)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
por: Moreno, Santiago, et al.
Publicado: (2023)

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine
por: Jeffrey, Jerry L., et al.
Publicado: (2022)

Rapid determination of SARS-CoV-2 antibody neutralization titer using Bio-Rad Bio-Plex correlates strongly with pseudovirus-determined neutralization titer
por: Heaps, Amy L., et al.
Publicado: (2023)

HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins
por: Brumme, Zabrina L., et al.
Publicado: (2009)

Molecular Epidemiology of HIV-1 in Ghana: Subtype Distribution, Drug Resistance and Coreceptor Usage
por: Appah, Anna, et al.
Publicado: (2022)

1562. Renal Outcomes after Switch from Oral Antiretroviral therapy (ART) to Long-acting injectable Cabotegravir/Rilpivirine (LAI CAB)
por: Ayala, Alvaro, et al.
Publicado: (2023)

Observational cohort study of rilpivirine (RPV) utilization in Europe
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2022)

High Levels of Dual-Class Drug Resistance in HIV-Infected Children Failing First-Line Antiretroviral Therapy in Southern Ethiopia
por: Tadesse, Birkneh Tilahun, et al.
Publicado: (2018)

1027. At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implementation Science Trial
por: Williams, Jamila K, et al.
Publicado: (2023)

Phase 2 Open-Label Study of Long-Term Safety, Tolerability, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive Adolescents Living with HIV-1
por: Lombaard, Johan, et al.
Publicado: (2022)

Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes
por: Mann, Jaclyn K, et al.
Publicado: (2013)

Technical and Regulatory Shortcomings of the TaqMan Version 1 HIV Viral Load Assay
por: Brumme, Chanson J., et al.
Publicado: (2012)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
por: Johnson, Kamile, et al.
Publicado: (2022)

Implication of autophagy in the antifibrogenic effect of Rilpivirine: when more is less
por: Lucantoni, Federico, et al.
Publicado: (2022)

Photophysical Exploration of Alectinib and Rilpivirine: Insights from Theory and Experiment
por: Zhang, Chun, et al.
Publicado: (2023)

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy
por: Gianotti, Nicola, et al.
Publicado: (2015)

Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy
por: Moffatt, Kurtis, et al.
Publicado: (2022)

Are We Ready for NGS HIV Drug Resistance Testing? The Second “Winnipeg Consensus” Symposium
por: Ji, Hezhao, et al.
Publicado: (2020)

HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy
por: Omondi, F. Harrison, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8m5oqds0sr9482bqvp1ad1j3n9